D-cycloserine

D-cycloserine is a lipid of Polyketides (PK) class. D-cycloserine is associated with abnormalities such as Inflammatory disorder, Asthma, Rheumatoid Arthritis, Multiple Sclerosis and Inflammatory Bowel Diseases. The involved functions are known as Cellular Infiltration, Vascular Permeability, Stimulus, antagonists and Kinase Inhibitors [MoA]. D-cycloserine often locates in Tissue membrane, Body tissue, Protoplasm, Endothelium and Cell Wall. The associated genes with D-cycloserine are Genome, serine O-sulfate, Polypeptides, alpha-aminobutyric acid, (S)-isomer and Genes, Reporter. The related lipids are Sphingolipids, Fatty Acids, Sterols, 25-hydroxycholesterol and Fatty Acids, Unsaturated.

Cross Reference

Introduction

To understand associated biological information of D-cycloserine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with D-cycloserine?

D-cycloserine is suspected in Tuberculosis, Inflammatory disorder, Asthma, Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Diseases and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with D-cycloserine

MeSH term MeSH ID Detail
Starvation D013217 47 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Total 2

PubChem Associated disorders and diseases

What pathways are associated with D-cycloserine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with D-cycloserine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with D-cycloserine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with D-cycloserine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with D-cycloserine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with D-cycloserine?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with D-cycloserine

Download all related citations
Per page 10 20 50 100 | Total 2271
Authors Title Published Journal PubMed Link
pmid:16296047
pmid:23342661
pmid:
Amorim Franco TM et al. Mechanism-Based Inhibition of the Mycobacterium tuberculosis Branched-Chain Aminotransferase by d- and l-Cycloserine. 2017 ACS Chem. Biol. pmid:28272868
Prosser GA and de Carvalho LP Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis. 2013 ACS Med Chem Lett pmid:24478820
VITEK V et al. [PRELIMINARY INFORMATION ON THE MECHANISM OF PSYCHOTROPIC ACTION OF CYCLOSERINE ISOMERS]. 1963 Act Nerv Super (Praha) pmid:14070633
Vojtĕchovský M An attempt to differentiate the effects of cycloserine isomers on psychological and physiological functions in healthy humans. 1965 Act Nerv Super (Praha) pmid:5326941
Brodan V and Kuhn E The effect of cycloserine on physical fitness in man. 1965 Act Nerv Super (Praha) pmid:5326942
Vítek V et al. Excretion of tryptophan and catecholamine metabolites after cycloserine isomers in man. 1965 Act Nerv Super (Praha) pmid:5882109
Bohdanecký Z Electrophysiological analysis of d- and l-cycloserine in rabbits. 1965 Act Nerv Super (Praha) pmid:5882110
Horáková Z et al. An experimental and clinical analysis of cycloserine--amino acid interaction. 1965 Act Nerv Super (Praha) pmid:5882111
Franková S Effects of cycloserine isomers on behavior in rats. 1965 Act Nerv Super (Praha) pmid:5882112
Mayer O et al. [On the selection of a suitable method for the determination of the effects of drugs on the central nervous system]. 1968 Act Nerv Super (Praha) pmid:5728316
MAYER O and VITEK V THE EFFECT OF CYCLOSERINE ON ENZYME ACTIVITY IN VITRO. 1965 Act Nerv Super (Praha) pmid:14316707
KUNCOVA S et al. [Neurological and psychiatric findings in Cycloserine therapy]. 1962 Act Nerv Super (Praha) pmid:14460535
Mayer O and Eybl V A contribution to the interpretation of the central nervous effects of cycloserine. 1970 Act Nerv Super (Praha) pmid:5418666
Gomazkow O [The effect of l- and d- cycloserine on hydrazine toxicity]. 1966 Acta Biol. Med. Ger. pmid:5983633
Hagmar B et al. Disseminated infection caused by Mycobacterium kansasii. Report of a case and brief review of the literature. 1969 Jul-Aug Acta Med Scand pmid:4185322
Miyamura S et al. An antibiotic produced by streptomyces strain No. 2608, identical with D-4-amino-3-isoxazolidone. 1970 Acta Med. Biol. (Niigata) pmid:5484572
Weiszfeiler G et al. A new mycobacterium species: Mycobacterium asiaticum n. sp. 1971 Acta Microbiol Acad Sci Hung pmid:5006093
Füzi M and Csukás Z New selective medium for the isolation of Clostridium perfringens. 1969 Acta Microbiol Acad Sci Hung pmid:4314336
Sáenz Lope E and Crespo Guiterrez D Nocardia asteroides primary cerebral abscess and secondary meningitis. 1977 Acta Neurochir (Wien) pmid:327760
Bonavita V [The neurochemistry of inhibition]. 1968 May-Jun Acta Neurol (Napoli) pmid:5712467
WEISERT O Some investigations relating to resistance determination of tubercle bacilli on cycloserine-containing Lowenstein-Jensen medium. 1958 Acta Pathol Microbiol Scand pmid:13532707
Engbaek HC et al. Non-photochromogenic mycobacteria serotype Davis. The inhomogeneity within the serological group and the relationship to Mycobacterium avium. 1970 Acta Pathol Microbiol Scand B Microbiol Immunol pmid:4322001
Kanetaka T and Oda T Toxic liver injuries. 1973 Acta Pathol. Jpn. pmid:4800729
Erhardt S and Engberg G Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. 2002 Acta Physiol. Scand. pmid:11982504
Vervliet B Learning and memory in conditioned fear extinction: effects of D-cycloserine. 2008 Acta Psychol (Amst) pmid:17707326
NAITO M (CHEMOTHERAPEUTIC ORIGINAL AND RE-TREATMENT OF PULMONARY TUBERCULOSIS.) 1963 Acta Tuberc Jpn pmid:14098723
BUTT H [Preliminary clinical report of experience in the combined treatment of pulmonary tuberculosis with Isoxyl, a new tuberculostatic agent]. 1963 Jan-Feb Acta Tuberc Pneumol Belg pmid:14041567
Böszörményi M et al. [Our initial clinical experience with rifomycin]. 1969 Acta Tuberc Pneumol Belg pmid:4906101
TANI P and POPPIUS H SIDE EFFECTS OF AN ANTITUBERCULOUS FIVE-DRUG REGIMEN: ETHIONAMIDE, CYCLOSERINE, PYRAZINAMIDE, VIOMYCIN AND ISONIAZID. 1963 Acta Tuberc Pneumol Scand pmid:14072347
SERI I Relationship of the bacteriostatic action of drugs to the number of tubercle bacilli. 1962 Acta Tuberc Pneumol Scand pmid:13988070
SMITH AE et al. A PRELIMINARY REPORT ON A NEW ANTITUBERCULOUS DRUG 4-AMINO-2-HYDROXY-PHENYL-1, 3, 4,-OXADIAZOL-2-OL WS 127. 1964 Acta Tuberc Pneumol Scand pmid:14234467
NOVAK M and JANCIK E SPUTUM CONVERSION IN CHRONIC TUBERCULOSIS WITH POLYRESISTANT BACILLI. 1964 Acta Tuberc Pneumol Scand pmid:14234473
HEJNY J DRUG-SENSITIVITY OF MYCOBACTERIUM BOVIS. 1964 Acta Tuberc Pneumol Scand pmid:14162309
ENGBAEK HC et al. DANISH PATIENTS WITH LUNG INFECTIONS CAUSED BY M. AVIUM AND ATYPICAL MYCOBACTERIA. 1964 Acta Tuberc Pneumol Scand Suppl pmid:14162300
Takács J and Imreh EZ Use of D-cycloserine bitartarate for selective isolation of Clostridia. 1975 Acta Vet Acad Sci Hung pmid:1233872
Akerstedt J and Hofshagen M Bacteriological investigation of infectious keratoconjunctivitis in Norwegian sheep. 2004 Acta Vet. Scand. pmid:15535083
Reizin FN and Zeitlyonok NA Physiology of interferonogenesis. II. Mechanism of action of alanine and serine on interferon production in chick embryo fibroblast cultures. 1971 Acta Virol. pmid:4397339
Kovács P The effect of beta-chloro D-alanine and L-cycloserine on the serine, phosphorus and palmitic acid uptake and metabolism of Tetrahymena lipids. 1999 Acta. Biol. Hung. pmid:10735173
Kennedy AP et al. A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. 2012 Addict Behav pmid:22578380
Yoon JH et al. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. 2013 Addict Behav pmid:22560371
Bates JH Treatment of tuberculosis. 1975 Adv Intern Med pmid:46687
Perkins HR Composition of bacterial cell walls in relation to antibiotic action. 1969 Adv Pharmacol pmid:4906304
Perkins HR Composition of bacterial cell walls in relation to antibiotic action. 1969 Adv Pharmacol Chemother pmid:4910169
Wong DT et al. Inhibition of amino acid transaminases by L-cycloserine. 1973 Adv. Enzyme Regul. pmid:4150977
Chopra I and Ball P Transport of antibiotics into bacteria. 1982 Adv. Microb. Physiol. pmid:6214162
Goff D The Therapeutic Role of d-Cycloserine in Schizophrenia. 2016 Adv. Pharmacol. pmid:27288073
Mondovi B et al. Proceedings: Effect of cycloserine on histaminase. 1975 Agents Actions pmid:816182
Luyirika E et al. A home-based approach to managing multi-drug resistant tuberculosis in Uganda: a case report. 2012 AIDS Res Ther pmid:22524486
Bhagwan S and Naidoo K Aetiology, clinical presentation, and outcome of meningitis in patients coinfected with human immunodeficiency virus and tuberculosis. 2011 AIDS Res Treat pmid:22216407
Bienkowski P et al. Discriminative stimulus effects of ethanol: lack of antagonism with N-methyl-D-aspartate and D-cycloserine. 1997 Jul-Aug Alcohol pmid:9209549
Vengeliene V et al. D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. 2008 Nov-Dec Alcohol Alcohol. pmid:18945754
Moraes Ferreira VM and Morato GS D-cycloserine blocks the effects of ethanol and HA-966 in rats tested in the elevated plus-maze. 1997 Alcohol. Clin. Exp. Res. pmid:9438524
Debrouse L et al. Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR glycine co-agonist site. 2013 Alcohol. Clin. Exp. Res. pmid:22934986
Groblewski PA et al. Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice. 2009 Alcohol. Clin. Exp. Res. pmid:19298331
Trevisan L et al. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors. 2008 Alcohol. Clin. Exp. Res. pmid:18028532
Thong BY Update on the management of antibiotic allergy. 2010 Allergy Asthma Immunol Res pmid:20358021
Randolph C et al. D-cycloserine treatment of Alzheimer disease. 1994 Alzheimer Dis Assoc Disord pmid:7986489
Santa Ana EJ et al. D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. 2015 Am J Addict pmid:25808169
Price KL et al. D-cycloserine and cocaine cue reactivity: preliminary findings. 2009 Am J Drug Alcohol Abuse pmid:20014913
Hofmann SG et al. Effects of D-cycloserine on craving to alcohol cues in problem drinkers: preliminary findings. 2012 Am J Drug Alcohol Abuse pmid:21851195
Peloquin CA and Berning SE Advice on treatment of drug-resistant tuberculosis. 1997 Am J Health Syst Pharm pmid:9075505
Posey DJ et al. A pilot study of D-cycloserine in subjects with autistic disorder. 2004 Am J Psychiatry pmid:15514414
Goff DC et al. D-cycloserine added to clozapine for patients with schizophrenia. 1996 Am J Psychiatry pmid:8942463
Shim SS et al. D-cycloserine augmentation for behavioral therapy. 2008 Am J Psychiatry pmid:18676606
Tsai GE et al. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. 1999 Am J Psychiatry pmid:10080566
Heresco-Levy U et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. 2002 Am J Psychiatry pmid:11870017
Kantrowitz JT et al. d-Cycloserine, an NMDA Glutamate Receptor Glycine Site Partial Agonist, Induces Acute Increases in Brain Glutamate Plus Glutamine and GABA Comparable to Ketamine. 2016 Am J Psychiatry pmid:27903101
Warren ZE et al. Identity crisis involving body image in a young man with autism. 2010 Am J Psychiatry pmid:21041252
Rothbaum BO et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. 2014 Am J Psychiatry pmid:24743802
Hofmann SG et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. 2013 Am J Psychiatry pmid:23599046
Neylan TC Pharmacologic augmentation of extinction learning during exposure therapy for PTSD. 2014 Am J Psychiatry pmid:24880503
Javitt DC Harnessing N-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studies. 2013 Am J Psychiatry pmid:23820828
Van Kammen DP gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. 1977 Am J Psychiatry pmid:835733
Buchanan RW et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. 2007 Am J Psychiatry pmid:17898352
Rothbaum BO et al. Response to Smith. 2014 Am J Psychiatry pmid:25756637
Goff DC et al. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. 1995 Am J Psychiatry pmid:7625475
Smith E Possible negative effects of extinction learning on outcomes for patients receiving exposure therapy. 2014 Am J Psychiatry pmid:25756636
Rothbaum BO and Ressler K Response to Granoff. 2014 Am J Psychiatry pmid:25756635
Granoff AL The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy. 2014 Am J Psychiatry pmid:25756634
Wilhelm S et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. 2008 Am J Psychiatry pmid:18245177
Rothbaum BO Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. 2008 Am J Psychiatry pmid:18316423
Tabarsi P et al. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. 2011 Am J Ther pmid:20535008
Baghaei P et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther pmid:20019591
STEENKEN W and WOLINSKY E Cycloserine: antituberculous activity in vitro and in the experimental animal. 1956 Am Rev Tuberc pmid:13302684
HOEPRICH PD ALANINE: CYCLOSERINE ANTAGONISM. I. SIGNIFICANCE OF PHENOMENON IN TESTING SUSCEPTIBILITY TO CYCLOSERINE. 1964 Am. J. Clin. Pathol. pmid:14124671
Hoeprich PD et al. Nocardial brain abscess cured with cycloserine and sulfonamides. 1968 Am. J. Med. Sci. pmid:5644095
WIEDMAN M and TURTZ AI Antibiotics in herpes simplex and an experimental and clinical investigation of cycloserine. 1959 Am. J. Ophthalmol. pmid:13844589
Jacobs LS and Kester M Sphingolipids as mediators of effects of platelet-derived growth factor in vascular smooth muscle cells. 1993 Am. J. Physiol. pmid:8214030
Baldwin EW et al. Efficacy of certain chemical agents in the treatment of leptospiruria in hamsters. 1972 Am. J. Vet. Res. pmid:4111742
Nair S and Baron H Tryptophan metabolism in tuberculosis. 1973 Am. Rev. Respir. Dis. pmid:4741891
David HL et al. Susceptibility of mycobacterial D-alanyl-D-alanine synthetase to D-cycloserine. 1969 Am. Rev. Respir. Dis. pmid:4981706
O'Brien RJ et al. Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. 1990 Am. Rev. Respir. Dis. pmid:2158257
Pines A Results after retreatment of advanced pulmonary tuberculosis with rifampin and other drugs. 1971 Am. Rev. Respir. Dis. pmid:4104090
BATTAGLIA B et al. Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children. 1961 Am. Rev. Respir. Dis. pmid:13687769
Schmidt JD et al. Cutaneous infection due to a Runyon group 3 atypical Mycobacterium. 1972 Am. Rev. Respir. Dis. pmid:5080716
CORPE RF et al. RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL. 1964 Am. Rev. Respir. Dis. pmid:14233802
HOK TT and SENG TK A COMPARATIVE STUDY OF THE SUSCEPTIBILITY TO STREPTOMYCIN, CYCLOSERINE, VIOMYCIN, AND KANAMYCIN OF TUBERCLE BACILLI FROM 100 PATIENTS NEVER TREATED WITH CYCLOSERINE, VIOMYCIN, OR KANAMYCIN. 1964 Am. Rev. Respir. Dis. pmid:14233803